- Home
- GHI vs IMMP Comparison
GHI vs IMMP Comparison
Compare GHI & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- IMMP
- Stock Information
- Founded
- GHI 1998
- IMMP 1987
- Country
- GHI United States
- IMMP Australia
- Employees
- GHI N/A
- IMMP N/A
- Industry
- GHI Finance: Consumer Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- GHI Finance
- IMMP Health Care
- Exchange
- GHI Nasdaq
- IMMP Nasdaq
- Market Cap
- GHI 269.5M
- IMMP 251.8M
- IPO Year
- GHI N/A
- IMMP N/A
- Fundamental
- Price
- GHI $10.86
- IMMP $1.64
- Analyst Decision
- GHI Strong Buy
- IMMP Buy
- Analyst Count
- GHI 4
- IMMP 1
- Target Price
- GHI $14.88
- IMMP $7.00
- AVG Volume (30 Days)
- GHI 63.7K
- IMMP 73.5K
- Earning Date
- GHI 08-07-2025
- IMMP 02-27-2025
- Dividend Yield
- GHI 13.67%
- IMMP N/A
- EPS Growth
- GHI N/A
- IMMP N/A
- EPS
- GHI N/A
- IMMP N/A
- Revenue
- GHI $27,326,828.00
- IMMP $3,019,249.00
- Revenue This Year
- GHI $228.92
- IMMP $50.37
- Revenue Next Year
- GHI $4.27
- IMMP N/A
- P/E Ratio
- GHI N/A
- IMMP N/A
- Revenue Growth
- GHI N/A
- IMMP 24.11
- 52 Week Low
- GHI $10.12
- IMMP $1.32
- 52 Week High
- GHI $14.51
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- GHI 49.88
- IMMP 40.76
- Support Level
- GHI $10.45
- IMMP $1.68
- Resistance Level
- GHI $11.12
- IMMP $1.85
- Average True Range (ATR)
- GHI 0.28
- IMMP 0.06
- MACD
- GHI 0.06
- IMMP -0.01
- Stochastic Oscillator
- GHI 71.51
- IMMP 4.17
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.